<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2017-3-46-51</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-581</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАКОТЕРАПИЯ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES</subject></subj-group></article-categories><title-group><article-title>НОВОЕ НАПРАВЛЕНИЕ В ОЦЕНКЕ ПРИВЕРЖЕННОСТИ ЛЕЧЕНИЮ — АКЦЕНТ НА ГЕРИАТРИЧЕСКИЕ СИНДРОМЫ</article-title><trans-title-group xml:lang="en"><trans-title>NOVEL DIRECTION IN ADHERENCE ASSESSMENT — FOCUS ON THE GERIATRIC SYNDROMES</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чукаева</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Chukaeva</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чукаева Ирина Ивановна — доктор медицинских наук, профессор, зав. кафедрой поликлинической терапии лечебного факультета.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">chukaeva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7825-5597</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ларина</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Larina</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ларина Вера Николаевна — доктор медицинских наук, профессор кафедры.</p><p>Москва, тел.: +7 (910) 473-35-66, SPIN-код 3674-9620</p></bio><bio xml:lang="en"/><email xlink:type="simple">larinav@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карпенко</surname><given-names>Д. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Karpenko</surname><given-names>D. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Карпенко Дмитрий ГеннадьевиМосквач — ассистент кафедры лечебного факультета.</p><p> </p><p> </p></bio><bio xml:lang="en"/><email xlink:type="simple">godpower@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ларин</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Larin</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ларин Владимир Геннадьевич— кандидат медицинских наук, доцент кафедры лечебного факультета.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">larinvladimir@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский национальный исследовательский медицинский Университет имени Н.И. Пирогова» Министерства здравоохранения РФ</institution></aff><aff xml:lang="en"><institution>N. I. Pirogov Russian National Research Medical University (RNRMU)</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО “Российский национальный исследовательский медицинский  университет имени Н. И. Пирогова” Министерства здравоохранения Российской Федерации</institution></aff><aff xml:lang="en"><institution>N. I. Pirogov Russian National Research Medical University (RNRMU)</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>20</day><month>06</month><year>2017</year></pub-date><volume>16</volume><issue>3</issue><fpage>46</fpage><lpage>51</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Чукаева И.И., Ларина В.Н., Карпенко Д.Г., Ларин В.Г., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Чукаева И.И., Ларина В.Н., Карпенко Д.Г., Ларин В.Г.</copyright-holder><copyright-holder xml:lang="en">Chukaeva I.I., Larina V.N., Karpenko D.G., Larin V.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/581">https://cardiovascular.elpub.ru/jour/article/view/581</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить факторы, определяющие приверженность оптимальной терапии пациентов пожилого возраста с хронической сердечной недостаточностью (ХСН), наблюдающихся в амбулаторных условиях.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В открытое, сравнительное одномоментное, нерандомизированное исследование были включены 80 пациентов с ХСН в возрасте ≥60 лет. Группу сравнения составили 40 пациентов (18 мужчин и 22 женщины) с заболеваниями сердечно-сосудистой системы  без  ХСН. У  пациентов  оценивались  индекс  коморбидности,   лабораторные    и   эхокардиографические    параметры, 6-минутный тест  ходьбы,  когнитивный статус,  приверженность лечению, проводилась двухфотонная рентгеновская абсорбциометрия. Критериями старческой астении считали наличие 3 признаков согласно  шкале  FRAIL  (Fatigue,  Resistance,   Ambulation, Illnesses, Loss of Weight).</p></sec><sec><title>Результаты</title><p>Результаты. Приверженными лечению были 40% пациентов с ХСН и 75% — группы сравнения (p&lt;0,001). При однофакторном анализе установлена связь приверженности лечению с уровнем когнитивного статуса по опроснику Mini-mental State Examination  — отношение шансов  (ОШ) 1,5;  95%  доверительный   интервал  (ДИ)  1,2-1,9 (р&lt;0,001), старческой астенией — ОШ 3,5; 95% ди 1,3-9,5 (р=0,011), остеопорозом — ОШ 2,98; 95% ДИ 1,0-8,9  (р=0,050),  коморбидностью по Charlson — ОШ 1,21; 95% ДИ 1,0-1,5 (р=0,050).</p></sec><sec><title>Заключение</title><p>Заключение. Приверженными лечению оказались 40% амбулаторных пациентов с ХСН в возрасте ≥60 лет. Множественная сопутствующая  патология,  нарушенный когнитивный статус,  остеопороз, старческая  астения оказывают негативное влияние на приверженность лечению лиц старшего возраста с ХСН.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To investigate on the factors determining the adherence to optimal treatment  in older  age  patients  with chronic  heart  failure (CHF) in outpatient setting.</p></sec><sec><title>Material and methods</title><p>Material and methods. Into the open, comparative single-movement non-randomized  study, 80 CHF patients  were included at the age ≥60 y.o. Comparison group consisted  of 40 patients (18 males, 22 females) with non-CHF cardiovascular  disorders.  Patients  underwent  the comorbidity assessment, laboratory and echocardiographic parameters, 6-minute walking test, cognitive status, treatment adherence, bi-photon x-ray absorptiometry. Criteria for frailty were 3 points by FRAIL (Fatigue, Resistance,  Ambulation, Illnesses, Loss of Weight).</p></sec><sec><title>Results</title><p>Results. The adherent to treatment were 40% of CHF patients, and 75% in comparison  group  (p&lt;0,001).  In monofactorial analysis there  was correlation of treatment  adherence with the level of cognition by Mini-mental  State  Examination — odds  ratio  (OR) 1,5;  95%  confidence interval  (CI) 1,2-1,9  (р&lt;0,001),  frailty  — OR 3,5;  95%  CI 1,3-9,5 (р=0,011),  osteoporosis  — OR  2,98;  95%  CI 1,0-8,9   (р=0,050), comorbidity by Charlson — OR 1,21; 95% CI 1,0-1,5 (р=0,050).</p></sec><sec><title>Conclusion</title><p>Conclusion. Adherent to treatment were 40% of outpatients with CHF at the  age  ≥60  y.o.  Multiple comorbidities,  impaired  cognition  status, osteoporosis, frailty influenced negatively the adherence to treatment in older persons with CHF.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>приверженность  лечению</kwd><kwd>пожилой возраст</kwd><kwd>сердечная недостаточность</kwd><kwd>старческая астения</kwd><kwd>остеопороз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>treatment   adherence</kwd><kwd>elderly</kwd><kwd>heart   failure</kwd><kwd>frailty</kwd><kwd>osteoporosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mareev VYu, Ageev FT, Arutyunov GP, et al. National recommendations of OCCH, PKO and PHMOT about diagnostics and treatment of HSN (fourth revision). Heart failure of 2013; 7 (81): p. 405. Russian (Мареев В. Ю., агеев Ф. т., арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОт по диагностике и лечению ХСН (четвертый пересмотр). Сердечная Недостаточность 2013; 7 (81); с. 405).</mixed-citation><mixed-citation xml:lang="en">Mareev VYu, Ageev FT, Arutyunov GP, et al. National recommendations of OCCH, PKO and PHMOT about diagnostics and treatment of HSN (fourth revision). Heart failure of 2013; 7 (81): p. 405. Russian (Мареев В. Ю., агеев Ф. т., арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОт по диагностике и лечению ХСН (четвертый пересмотр). Сердечная Недостаточность 2013; 7 (81); с. 405).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Störk S, Kavoliuniene A, Vinereanu D, et al. What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative. Eur J of Heart Fail 2016; 18: 66-70.</mixed-citation><mixed-citation xml:lang="en">Störk S, Kavoliuniene A, Vinereanu D, et al. What does the lay public know about heart failure? Findings from the Heart Failure Awareness Day Initiative. Eur J of Heart Fail 2016; 18: 66-70.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Мentz R, Kelly J, von Lueder T, et al. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. JACC 2014; 64(21): 2281-93.</mixed-citation><mixed-citation xml:lang="en">Мentz R, Kelly J, von Lueder T, et al. Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. JACC 2014; 64(21): 2281-93.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Guyatt G, Thompson P, Berman L, et al. How should we measure function in patients with chronic heart and lung disease? J Chron Dis 1985; 38, Suppl 6: 517-24.</mixed-citation><mixed-citation xml:lang="en">Guyatt G, Thompson P, Berman L, et al. How should we measure function in patients with chronic heart and lung disease? J Chron Dis 1985; 38, Suppl 6: 517-24.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Charlson M, Pompei P, Ales K, Mackenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373-83.</mixed-citation><mixed-citation xml:lang="en">Charlson M, Pompei P, Ales K, Mackenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373-83.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Morley J, Malmstrom T, Miller D. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 2012; 16 (7): 601-8.</mixed-citation><mixed-citation xml:lang="en">Morley J, Malmstrom T, Miller D. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 2012; 16 (7): 601-8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; doi:10.1093/eurheartj/ehw128.</mixed-citation><mixed-citation xml:lang="en">Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 2016; doi:10.1093/eurheartj/ehw128.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Beard J, Officer A, de Carvalho I, et al. The World report on ageing and health: a policy framework for healthy ageing. Lancet 2016; 387: 2145-54.</mixed-citation><mixed-citation xml:lang="en">Beard J, Officer A, de Carvalho I, et al. The World report on ageing and health: a policy framework for healthy ageing. Lancet 2016; 387: 2145-54.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Efremova EV, Mevzorov MV, Sabitov IA. Commitment to treatment of patients with chronic heart failure in the conditions of a komorbidnost. Clinical of medicine 2015; 10: 20-4. Russian (ефремова е. В., Мевзоров М. В., Сабитов и. а. Приверженность к лечению больных с хронической сердечной недостаточностью в условиях коморбидности. Клиническая медицина 2015;10: 20-4).</mixed-citation><mixed-citation xml:lang="en">Efremova EV, Mevzorov MV, Sabitov IA. Commitment to treatment of patients with chronic heart failure in the conditions of a komorbidnost. Clinical of medicine 2015; 10: 20-4. Russian (ефремова е. В., Мевзоров М. В., Сабитов и. а. Приверженность к лечению больных с хронической сердечной недостаточностью в условиях коморбидности. Клиническая медицина 2015;10: 20-4).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Yancy C, Fonarow G, Albert N, et al. Adherence to Guideline-Recommended Adjunctive Heart Failure Therapies Among Outpatient Cardiology Practices (Findings from IMPROVE HF). Am J Cardiol 2010; 105: 255-60.</mixed-citation><mixed-citation xml:lang="en">Yancy C, Fonarow G, Albert N, et al. Adherence to Guideline-Recommended Adjunctive Heart Failure Therapies Among Outpatient Cardiology Practices (Findings from IMPROVE HF). Am J Cardiol 2010; 105: 255-60.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">McLennan S, Pearson S, Cameron J, Stewart S. Prognostic importance of cognitive impairment in chronic heart failure patients: Does specialist management make a difference? Eur J Heart Failure 2006; 8: 494-501.</mixed-citation><mixed-citation xml:lang="en">McLennan S, Pearson S, Cameron J, Stewart S. Prognostic importance of cognitive impairment in chronic heart failure patients: Does specialist management make a difference? Eur J Heart Failure 2006; 8: 494-501.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Vogels R, Scheltens P, Schroeder-Tanka J, Weinstein H. Cognitive impairment in heart failure: A systematic review of the literature. Eur J Heart Fail 2007; 5 (9): 440-9.</mixed-citation><mixed-citation xml:lang="en">Vogels R, Scheltens P, Schroeder-Tanka J, Weinstein H. Cognitive impairment in heart failure: A systematic review of the literature. Eur J Heart Fail 2007; 5 (9): 440-9.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Murad K, Goff D, Morgan T, et al. Burden of Comorbidities and Functional and Cognitive Impairments in Elderly Patients at the Initial Diagnosis of Heart Failure and Their Impact on Total Mortality: The Cardiovascular Health Study. JACC Heart Fail 2015; 3 (7): 542-50.</mixed-citation><mixed-citation xml:lang="en">Murad K, Goff D, Morgan T, et al. Burden of Comorbidities and Functional and Cognitive Impairments in Elderly Patients at the Initial Diagnosis of Heart Failure and Their Impact on Total Mortality: The Cardiovascular Health Study. JACC Heart Fail 2015; 3 (7): 542-50.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">van Deursen V, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J of Heart Fail 2014; 16: 103-11.</mixed-citation><mixed-citation xml:lang="en">van Deursen V, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J of Heart Fail 2014; 16: 103-11.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Luttik M, Jaarsma T, van Geel P, et al. Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study. Eur J Heart Fail 2014; 16: 1241-8.</mixed-citation><mixed-citation xml:lang="en">Luttik M, Jaarsma T, van Geel P, et al. Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study. Eur J Heart Fail 2014; 16: 1241-8.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
